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Background: Choriocarcinoma is a gestational trophoblastic tumor which causes high mortality if left untreated.
MicroRNAs (miRNAs) are small non protein-coding RNAs which inhibit target gene expression. The role of miRNAs
in choriocarcinoma, however, is not well understood. In this study, we examined the effect of miR-34a in
choriocarcinoma.
Methods: MiR-34a was either inhibited or ectopically expressed transiently in two choriocarcinoma cell lines
(BeWo and JEG-3) respectively. Its actions on cell invasion, proliferation and colony formation at low cell density
were examined. The miR-34a putative target Notch ligand Delta-like 1 (DLL1) was identified by adoption of different
approaches including: in-silico analysis, functional luciferase assay and western blotting. Real-time quantitative
polymerase chain reaction was used to quantify changes in the expression of matrix proteinase in the treated cells.
To nullify the effect of miR-34a ectopic expression, we activated Notch signaling through force-expression of the
Notch intracellular domain in the miR-34a force-expressed cells. In addition, we studied the importance of DLL1 in
BeWo cell invasion through ligand stimulation and antibody inhibition. Furthermore, the induction in tumor
formation of miR-34a-inhibited BeWo cells in SCID mice was investigated.
Results: Transient miR-34a force-expression significantly suppressed cell proliferation and invasion in BeWo and
JEG-3 cells. In silicon miRNA target prediction, luciferase functional assays and Western blotting analysis
demonstrated that miR-34a regulated DLL1 expression in both cell lines. Although force-expression of miR-34a
suppressed the expression of DLL1 and NOTCH1, the extent of suppression was higher in DLL1 than NOTCH1 in
both cell lines. MiR-34a-mediated DLL1 suppression led to reduced matrix metallopeptidase 9 and urokinase-type
plasminogen activator expression. The effect of miR-34a on cell invasion was partially nullified by Notch signaling
activation. DLL1 ligand stimulated while anti-DLL1 antibody treatment suppressed cell invasion. Mice inoculated
with BeWo cells transfected with miR-34a inhibitor had significantly larger xenografts and stronger DLL1 expression
than those with cells transfected with the control inhibitor.
Conclusions: MiR-34a reduced cell proliferation and invasiveness, at least, partially through its inhibitory effect on DLL1.
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Choriocarcinoma is a highly malignant trophoblastic
tumor characterized by abnormal trophoblastic hyper-
plasia and anaplasia. It can be derived either from a nor-
mal or pathological pregnancy like molar pregnancies,
induced/spontaneous abortions, ectopic pregnancies and
preterm deliveries [1]. Although choriocarcinoma is a
rare disease, if left untreated, can spread rapidly and has
a mortality rate of nearly 100% [2]. During organ trans-
plantation, dissemination of choriocarcinoma cells from
donors to recipients can lead to quick death of the reci-
pients [3]. Our knowledge on choriocarcinoma is very
limited due to its rarity and lack of proper controls in
studies. Besides, heterogeneous causes of the disease
make study of the disease much more complicated; cyto-
genetic analyses indicate that nearly all chromosomes
can be affected and no consistent abnormality has been
identified in choriocarcinoma [4].
MicroRNAs (miRNAs) are small untranslated RNAs
that inhibit expression of target genes through transla-
tional inhibition or transcriptional silencing [5]. Bioinfor-
matics analysis predicts that 30% of all the protein-coding
genes are targets of miRNAs [6]. MiRNAs is involved in
various physiological processes while aberrant miRNA
expressions are usually pathological. Previously, only the
roles of miR-141 and miR-199b in choriocarcinoma were
reported [7,8]. The significance of other miRNAs in
choriocarcinoma is not known.
The miR-34 family members share high sequence ho-
mology [9]. Among these, miR-34a is one of the earliest
known miRNA tumor suppressor and is directly transacti-
vated by p53 [10,11]. In this study, we used BeWo and
JEG-3 cells as model to examine the role of miR-34a as a
tumor-suppressor in choriocarcinoma. These 2 cell lines
are widely used for the study of trophoblast physiology
and trophoblastic cancer. Hence, we used gain/loss
of function approach and demonstrated that miR-34a
affected proliferation, colony-formation and invasion of
choriocarcinoma cells in vitro and the tumor formation
capability in vivo.
Notch signaling is a short range communication
transducer system which is important in many physio-
logical and pathological conditions [12] and is highly
conserved. There are 4 Notch receptors (Notch 1–4)
and 5 Notch ligands (DLL1, 3, 4 and Jagged1, 2) and
belongs to the type I membrane-bound proteins. Upon
ligand binding, the intracellular domain of the Notch
receptor (NCID) is cleaved and translocated into the
nucleus, where it acts as a transcriptional factor for tar-
get gene activation [13]. Bioinformatics analyses suggest
that the Notch ligand, delta-like one (DLL1) is a target
of miR-34a. This was further confirmed in the present
study by the 3’-untranslated region (UTR) luciferase
functional assay. The data also demonstrated that DLL1and Notch signaling mediated the action of miR-34a in
cell invasion.
Methods
Cell culture
The BeWo cells and JEG-3 cells (American Type
Culture Collection, Manassas, VA) were cultured re-
spectively in F12K medium or DMEM medium,
(Invitrogen, Carlsad, CA) supplemented with 10% fetal
bovine serum (FBS), 50 U/ml of penicillin and 50 μg/ml
of streptomycin (Invitrogen). For force-expression of
miR-34a, 1 × 105 cells were seeded in 12-well culture
plates 1 day before transfection either with 50 nM of
precursor of miR-34a (pre-miR-34a) or pre-miR-Scramble
(Negative Control #1, Ambion, Austin, TX) by Lipofecta-
mine 2000 (Invitrogen). For activation of Notch signaling,
a Notch NCID expression plasmid (pCDNA6-Notch
NCID, a kind gift from Prof. Jon Aster, Brigham and
Women’s Hospital and Harvard Medical School, Boston,
Massachusetts, USA) was used. In control experiments, the
cells were transfected with an empty vector (pCDNA6).
Proliferation assay
Cell proliferation was estimated by the CyQuantW cell
proliferation assay (Invitrogen) according to the manu-
facturer’s protocol. Fluorescence signal with excitation
at 485 nm and emission at 530 nm was measured by
a microplate reader (Tecan Group Ltd, Männedorf,
Switzerland).
Invasion assay
We used the BD Matrigel Invasion Chamber (8-μm pore
size; BD Biosciences, Franklin Lakes, NJ) to quantify cell in-
vasion. The transfected cells in FBS-free culture medium
were seeded onto the upper chamber while the lower
chamber was filled with normal FBS-containing medium.
For DLL1 stimulation, 2.5 μg of recombinant DLL1 (R&D
systems, Minneapolis, MN) was added to the upper cham-
ber. In the control experiment, the same volume of DMSO
was added to the cells. For antibody inhibition, 5 μg of
polyclonal anti-DLL1 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) was added to the upper chamber during
seeding, and fresh antibody was added every 24 hours.
After 48 hours, the cells remained in the upper chamber
were removed by cotton swabs, whilst those that had
invaded through the matrix between the two chambers
were visualized by staining with 0.1% of crystal violet
(Sigma-Aldrich, St Louis, MO). To quantify the invasion re-
sult, the dye was dissolved in 10% acetic acid and the ab-
sorbance was measured by a microplate reader. Parallel
experiments on cell proliferation were performed to esti-
mate the effect of cell proliferation on the results of cell
invasion.
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quantitative real-time quantitative PCRs (RT-qPCR)
Total RNA was prepared by using the mirVana™ miRNA
Isolation Kit (Ambion) according to the manufacturer’s
protocol. For assaying mRNA, first-strand cDNA was
synthesized by the High Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems, Foster City, CA) and the
target gene expression was quantified by the TaqManW
Gene Expression Assays (Applied Biosystems) using an
Applied Biosystems 7500 Detection system (Applied
Biosystems). The expression of mRNA was determined
from the threshold cycle (Ct), and the relative expression
levels were calculated by the 2-ΔΔCt method [14]. The rela-
tive expression levels were normalized with the expression
of 18S mRNA. For measuring miRNAs, the first-strand
cDNA was synthesized by the TaqManW MicroRNA
Reverse Transcription kit (Applied Biosystems) and the
miRNA expression was quantified by the TaqManW Micro-
RNA assay (Applied Biosystems). The relative expression of
miR-34a was calculated as the above and the levels were
normalized with the expression of the small RNA RNU6B.
3’UTR functional luciferase assays
Oligonucleotides were synthesized according to the nu-
cleotide sequence of potential miR-34a binding regions
identified by TargetScan5.2 on DLL1 (355–361 of DLL1
3’UTR, NCBI reference sequence: NM_005618.3). Spe-
cific primers were purchased from Invitrogen (Forward:
5’-TCCTCGAGAA TTAGAAACAC AAACACTGCC
TGCGGCCGCT G-3’ and Reverse: 5’-CAGCGGCCGC
AGGCAGTGTT TGTGTTTCTA ATTCTCGAGG A-3’).
The DNA fragment was cloned into the Xho I and Not I
sites of the pSiCheck™-2vector (Promega, Madison, WI).
The vector was transfected with either pre-miR-34a or
pre-Scramble into the cells (Ambion). At 48-hour post-
transfection, the cells were lysed and the luciferase acti-
vities in the lysate were measured by the Dual Luciferase
Reporter Assay System (Promega). The effect of the
miRNA was measured by the activity of the Renilla lucifer-
ase normalized to that of the firefly luciferase. To test the
specificity of the interaction between miR-34a and 3’UTR
of DLL1, the miR-34a seed binding region on the 3’UTR
of DLL1 was mutated. The mutant construct was gene-
rated with specific primers (Forward: 5’-TCCTCGAGAA
TTAGAAACAC AAAGAGTACT TGCGGCCGCT G-3’
and Reverse: 5’-CAGCGGCCGC AAGTACTCTT TGTG
TTTCTA ATTCTCGAGG A-3’; underlined regions
denote the mutated sequences) and cloned into the
pSiCheck™-2vector as described above.
Colony formation assay
BeWo and JEG-3 cells transfected with pre-miR-34a or
pre-Scramble were seeded at a density of 20 cells/cm2 in
normal culture medium as stated as the above and allowedto grow for 2 weeks. The colonies were then stained with
0.1% crystal violet (Sigma-Aldrich), washed with PBS and
their number was counted. Images of the colonies were
scanned with a gel documentation system (AlphaImagerW
HP, Alpha Innotech Corporation, San Leandro, CA).In vivo tumorigenicity assay
The study protocol was approved by the Committee on the
Use of Live Animals in Teaching and Research at the
University of Hong Kong. BeWo cells were transfected
either with 50 nM of miR-34a miRCURY LNA™ knock-
down probe or control (Exiqon, Vedbaek, Denmark). The
transfected BeWo cells (1 × 106) were resuspended in
100 μl of PBS, mixed with 100 μl of matrigel (BD Bios-
ciences), and injected subcutaneously into both sides of the
posterior flanks of 4- to 6-week-old female B-17/Icr-scid
(SCID) mice. The animals were sacrificed after 4 weeks.
Four mice were used in each experiment and the experi-
ment was repeated for 5 times independently.Western blot analysis
Cell lysates were prepared as described [15]. The protein
expression of DLL1, NOTCH1 and β-actin were detected
using specific anti-DLL1 (Santa Cruz, sc-9102), anti-
NOTCH1 (Santa Cruz, sc-6014) and anti-β-actin antibodies
(Santa Cruz, sc-47778). The denatured protein samples
were resolved on a 8% denaturing SDS-PAGE and trans-
ferred to a nitrocellulose membrane. The membrane was
blocked withTris-buffered saline containing 5% nonfat milk
and 0.5% Tween 20 (blocking buffer) at room temperature
for 1 hour. Hybridization was performed at 4°C overnight
(1oAb 1:1000 for DLL1 and NOTCH1, 1:10000 for β-actin),
followed by extensive washing and incubation with appro-
priate horseradish peroxidase-conjugated secondary anti-
body (1:2500) in blocking buffer for 1 hour at room
temperature. The protein bands were detected by chemilu-
minescence detection.Immunohistochemical staining
Tissues preparation and immunohistochemistry were
performed as described [16]. Briefly, antigen retrieval
was performed by heating the sections in 1X target anti-
gen retrieval solution (Dako, Glostrup, Denmark). Non-
specific binding was blocked by incubating the tissue
sections in PBS containing 5% serum (Sigma-Aldrich)
and 0.1% Tween 20. DLL1 immunoreactivities were
detected by successive incubation with specific antibody
against DLL1 (Santa Cruz), biotinylated polyclonal
rabbit anti-goat IgG (Dako) and Strep ABComplex/
Horseradish Peroxidase HRP (Vector Laboratories,
Burlingame, CA). Signal was visualized with 3,3’-diami-
nobenzidine (Dako).
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Each experiment was repeated independently for at least 3
times. All the values were reported as means ± SD. Diffe-
rences between the treatment and the control groups were
analyzed by Kruskal-Wallis test. p < 0.05 was considered
as statistically significant.Results
MiR-34a reduces proliferation and invasion of
choriocarcinoma cell lines
We first studied the biological effect of miR-34a in two
choriocarcinoma cell lines BeWo and JEG-3 through
transfection of pre-miR-34a. We examined the level of
miR-34a in the cells at day 3 and day 10 post-transfec-
tion, and found that the pre-miR-34a transfected cells
had at least ~80-fold higher levels of miR-34a than the
control (Additional file 1: Figure S1). Ectopic expression
of miR-34a did not significantly affect BeWo cells proli-
feration in the first 72-hour post-transfection (Figure 1A),
but a significant reduction was observed after 7 days
(168 hours) of transfection (p < 0.05). The colony forma-
tion ability in low seeding density was evaluated 2 weeks
post-transfection and the pre-miR-34a transfected cells
had around 2–3 times lower colony-forming ability than
the scramble precursor transfected cells (Figure 1B,
p < 0.05).
Next, we assessed the action of miR-34a on cell inva-
sion. The miR-34a force-expressed cells were allowed to
invade a matrigel membrane for 48 hours. It was found
that the invasiveness of the miR-34a force-expressed
choriocarcinoma cells was significantly decreased when
compared with the control group (Figure 1C).Delta-like one (DLL1) is a target of miR-34a in
choriocarcinoma cells
Since miRNA is non-translational, it must exert its effect
through regulating target genes. To determine the target
gene of miR-34a, we first used in-silico miRNA target
prediction tools to find the potential target of miR-34a.
Both TargetScan 5.2 (http://www.targetscan.org/) and Pict-
Tar (http://pictar.mdc-berlin.de/) predict that the Notch
ligand DLL1 is a potential target of miR-34a (Figure 2A).
We examined the expression of DLL1 in BeWo and JEG-3
cells upon miR-34a force-expression for 3 days, and found
that the DLL1 protein level was greatly reduced by miR-
34a but not by the scramble miRNA precursor.
NOTCH1 is a known miR-34a targeted gene in chorio-
carcinoma cells [15]. We compared the action of miR-34a
on the protein expression of NOTCH1 and DLL1. It was
found that miR-34a force-expression decreased the level
of DLL1 to a greater extent than that of NOTCH1 in both
BeWo and JEG-3 cells (Figure 2B). Therefore, we focused
our study on DLL1.We further examined whether there is a direct inter-
action between miR-34a and DLL1. We constructed a
luciferase reporter carrying the 3’UTR of DLL1 and
transfected the reporter with either the pre-miR-34a or
scramble miRNA precursor into BeWo cells. Force-
expression of miR-34a reduced the luciferase reporter
activity by more than 50% (p < 0.05, Figure 2C). To de-
termine the specificity of the interaction, another re-
porter vector carrying a mutation at the putative seed
binding sequence was constructed. Force-expression of
miR-34a had no significant effect on the reporter activ-
ities of the mutant construct, confirming the specificity
of the action of miR-34a on DLL1.
To study the mechanism of action of miR-34a on DLL1
expression, we determined the mRNA expression of DLL1
upon miR-34a force-expression, RT-qPCR revealed that
the treatment and the control groups had similar levels of
the DLL1 mRNA (Figure 2D). The observation indicated
that miR-34a regulated DLL1 expression in choriocarcin-
oma cells through translational inhibition. Similarly, the
expression of NOTCH1 mRNA was not affected by miR-
34a force-expression. To confirm that the action of miR-
34a on DLL1 modulated Notch signaling, we examined
the expression of the Notch signaling target gene Hairy
Enhancer of Split-1 protein (Hes-1) and found that it was
reduced upon force-expression of miR-34a in both cell
lines (Figure 2E).
MiR-34a regulates invasion of BeWo cells through the
Notch signaling pathway
DLL1 treatment significantly increased cell invasion
(Figure 3A and B), whilst treatment with anti-DLL1 anti-
body inhibited around 30% of the invasion. On the other
hand, force-expression of NCID increased cell invasion
by more than 2-fold. These treatments did not signifi-
cantly affect proliferation as reflected by the cell prolif-
eration assay (Figure 3C). We next determined the role
of Notch signaling activation on the action of miR-34a
on cell invasion. As shown in Figure 4A, the effect of
force-expression of miR-34a was nearly completely nulli-
fied by Notch signaling activation but not by the control
treatment. Again, the treatments did not affect cell pro-
liferation (Figure 4B). Moreover, RT-qPCR showed that
miR-34a force-expression reduced around 35% of the
urokinase-type plasminogen activator (uPA) and 55% of
the matrix metalloproteinase-9 (MMP9) expression
(Figure 4C). Thus, we concluded that miR-34a force-ex-
pression reduced the invasiveness of BeWo cells through
DLL1 and the Notch signaling pathway.
MiR-34a knockdown enhances tumor growth in vivo
To examine whether miR-34a knockdown affects tumor
formation in vivo, we subcutaneously inoculated miR-
34a knockdown BeWo cells or scramble knockdown
Figure 1 Effect of miR-34a on choriocarcinoma cells. (A) Cell proliferation upon miR-34a ectopic expression. Significantly slower proliferation
was observed in cells with miR-34a ectopic expression at 168 hours post-transfection. (B) Colony formation of pre-miR-34a transfected cells
seeded at low density. The colonies were visualized after staining with crystal violet at 14-days post-transfection. The bars in the chart represent
mean ± SD of number of colonies from 3 independent experiments. *p < 0.05. (C) Suppression of invasion of BeWo and JEG-3 cells upon miR-34a
ectopic expression. Representative images of the invaded cells. The graph represents the extent of invasion of the pre-miR-34a transfected cells
relative to the control cells.
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Figure 2 Validation of DLL1 as a miR-34a target gene.
(A) Computational algorithm showing the seed region of
miR-34a at the 3’UTR of DLL1. (B) Western blotting analysis of
the expressions of DLL1 and NOTCH1 upon miR-34a
force-expression. (C) Functional luciferase assay. Significant
differences was found between scramble and pre-miR-34a on
wild-type 3’UTR construct but not with construct carrying a
mutated seed region (n = 4). (D & E) Quantitative real-time PCR
analysis showing the mRNA levels of DLL1, NOTCH1
(D) and Hes-1 (E) between pre-miR-34a and scramble
precursor transfected cells (n = 4).*p < 0.05.
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increased the weight of the xenografts by day 28 when
compared with xenografts transfected with scramble
control (p < 0.05, Figure 5A-C). Immunostaining showed
that miR-34a knockdown increased the expression of
DLL1 in the xenografts when compared to the control
(Figure 5D).
Discussion and conclusions
MiR-34 family members were first identified as tumor
suppressors [10,11] and are associated with a variety of
tumors [17]. However, their roles in pathogenesis are
poorly understood. Recently, their family members were
shown to regulate neurite outgrowth, morphology and
functions [18], late steps of spermatogenesis [19] and
modulate the first cleavage of mouse preimplantation
embryos [20]. In this study, we explored the action of
miR-34a in choriocarcinoma cell lines.
We observed a delayed action of miR-34a force-
expression on proliferation, in which a significant inhib-
ition was detected only at 168-hour post-transfection
whereas a decrease in DLL1 protein level occurred at
72-hour post-transfection. Similar finding was reported
in glioma stem cells [21]. DLL1 is a transmembrane lig-
and of the Notch signaling pathway. The delayed action
could be due to the need of adequate physical contact
between adjacent cells for sufficient activation of Notch
signaling before an effect on proliferation could be
observed, and the contact was inadequate in the early
part of the experiment when the cell density was low.
The explanation is consistent with a previous report
demonstrating that another Notch-ligand JAG1 affects
proliferation only when the cell density is above certain
density [22].
p53 has a key role in inducing apoptosis and exerts its
tumor-suppressive effect partially through miR-34a [10].
In many solid tumors, p53 malfunction is a consequence
of gene mutation. However, direct sequencing cannot
detect mutation in p53 cDNA of gestational tropho-
blastic disease [23,24]. In fact, p53 is highly expressed in
choriocarcinoma [25] and is associated with a more ag-
gressive behavior [26]. This is in contrast to many other
cells, which undergo programmed cell death when the
level of p53 is high. It is possible that there is a malfunc-
tion of the p53 effectors in the choriocarcinoma enabling
the cells to survive under such condition. Suppression
of the apoptosis-stimulating proteins of p53 (ASPP1), a
member of the p53 transcriptional complex, through
promoter hypermethylation in choriocarcinoma cell lines
supports this possibility [27]. In fact, force-expression of
ASPP1 in choriocarcinoma cell line has profound effects
on reducing tumorigenecity [27]. The present study sug-
gests that miR-34a is another component of the p53 net-
work important in tumor suppression.
Figure 4 MiR-34a reduces cell invasion through Notch signaling. (A) Representative images showing that Notch activation nearly fully
nullified the inhibitory effect of miR-34a force-expression on cell invasion. (B) Invasion expressed as relative to the untreated control cells (n = 4).
(C) Proliferation of the cells. Parallel experiment demonstrated no significant effect of treatments on proliferation of the transfected cells.
(D) uPA and MMP9 mRNA expression in the transfected cells as determined by RT-qPCRs (n = 4) *p < 0.05.
Figure 3 Role of DLL1 and Notch signaling in cell invasion. (A) Representative pictures showing increase in cell invasion after activation of
Notch signaling by transfection of NCID and recombinant DLL1 treatment. The invasion of the cells was reduced by treatment with anti-DLL1
antibody. (B) Quantification of cell invasion relative to the untreated control cells. (n = 4). (C) Cell proliferation expressed as relative to the
respective control cells. (n = 4).*p < 0.05.
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Figure 5 MiR-34a inhibition enhances tumor growth in vivo. (A) Weight of tumor xenografts excised from SCID mice after miR-34a
knockdown. (B) Representative tumor xenografts excised from SCID mice. (C) Representative picture of SCID mice receiving subcutaneous
inoculation of BeWo cells before excising for tumor xenografts. (D) Representative views of expression of DLL1 in xenografts upon miR-34a
knockdown or scramble knockdown (Magnification: 200×).
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tumor invasion is an early marker of metastasis. Thus,
understanding of tumor invasion is of great importance.
MiR-34a inhibits invasion in a number of tumors inclu-
ding prostate cancer [28], colon cancer [29], cervical
cancer [15] and hepatocellular cancer [30]. Our findings
support these observations and further show that miR-
34a regulates invasion through DLL1 leading eventually
to reduction in the expression of the matrix degrading
enzymes.
DLL1 is a target of miR-34a in medulloblastoma [31].
As the targets of miRNA are cell context-dependent
[32], a reporter assay was conducted to confirm the dir-
ect interaction of miR-34a with DLL1 in choriocarcin-
oma. In fact, several Notch receptors and ligands have
been demonstrated to be targets of miR-34a. These in-
clude DLL1 ([31]; this study), JAG1[15,33], NOTCH1
[15,34], NOTCH2 [34]. In this study, we also demon-
strated that miR-34a inhibits NOTCH1 expression by
translational inhibition in choriocarcinoma cells.
Notch signaling components are expressed in the
trophoblast during normal pregnancy [35]. Apart from
choriocarcinoma cell lines [15], there is no study on Notch
signaling in primary choriocarcinoma tissues. In other
cancers, aberrant expression and activation of Notch sig-
naling are associated with changes in cell invasion [36]. In
this study, we found that DLL1/Notch signaling mediatedthe action of miR-34a; activation of the Notch signaling
through NCID transfection nullified the action of force-
expression of miR-34a on suppressing the invasion of
BeWo cells. As there are at least 3 miR-34a-targeted
Notch components, DLL1, NOTCH1 and JAG1 in chorio-
carcinoma cells, the observed tumor suppressive effect of
miR-34a and its action on Hes-1 could be a summation
effect of miR-34a on these Notch targets.
Our data showed that miR-34a force-expression sup-
pressed invasion by reducing the expression of MMP-9
and uPA. Both enzymes are regulated by AP-1 tran-
scription factor complex [29,37]. Choriocarcinomas
have a strong expression of members of the AP-1 family
including, c-Jun, Jun D and Fra1 [38]. MiR-34a may
regulate AP-1 complex through two pathways. The first
pathway is the direct action of miRNA on its target,
Fra-1 [29], which is an integral part of AP-1. One of the
downstream effectors of Notch signaling is AP-1.
Therefore, the second pathway is indirectly through
Notch signaling. As stated above, several components of
the Notch signaling are target of the miR-34 family
members [15,31,33,34]. In this study, Notch signaling
activation nearly fully nullified the effect of miR-34a in-
dicating the Notch pathway being the major miR-34a
target for controlling cell invasion in our model.
Notch signaling plays an important role in cancer. It is
essential for cell survival and has anti-apoptotic roles
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possess stem-cell-like properties and exhibit enhanced
chemoresistance and malignancy capabilities [42]. The
Notch, Hedgehog and Wnt signaling pathways are the
strongest stem cell promoting pathways keeping the
stem cells in an undifferentiated state. It has been sug-
gested that treatment targeting these pathways can in-
hibit tumor relapse and improve overall cancer survival
[43,44]. For example, activation of the Notch signaling
pathway can determine cancer cell stemness and tumori-
genicity in certain cases [31,45]. Currently, there are evi-
dences indicating that miR-34a is at least a suppressor of
the Notch [15,33] and the Wnt signaling pathway [46],
and that miR-34a force-expression negatively affects
tumor-propagating cells through inhibiting DLL1 in
medulloblastoma [31]. Our study provides further evi-
dence that miR-34a reduces tumorigenicity through
DLL1 but whether miR-34a regulates cancer stem cells
stemness in choriocarcinoma remains to be determined.
In summary, this study demonstrates that miR-34a is a
tumor suppressive miRNA in choriocarcinoma cells. The
miRNA exerts its biological activities through regulation
of the Notch ligand DLL1. It is possible that miR-34a
can be used as a therapeutic target for treating chorio-
carcinoma in the future.
Additional file
Additional file 1: Figure S1. Expression level of miR-34a at different
time points post-transfection. Levels of miR-34a were determined by
TaqMan miRNA assays and normalized by RNU6B as described in the
Materials and Methods. Relative expression level was expressed as fold
over control.
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